| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
SLAMF3/7 are highly expressed on multiple myeloma (MM) cells, although their role in MM pathogenesis remains unclear. In this study, we investigated the functions of those molecules to elucidate MM pathophysiology and attempted to develop new therapeutic strategies. High levels of SLAMF expression were detected in most patients. The proliferative potential and percentage of antimyeloma drug-induced apoptotic cells in SLAMF+ MM cells were significantly higher and lower than in SLAMF- cells, respectively. And we identified new adaptor proteins that could mediate activation signaling in MM cells. The serum levels of soluble SLAMF in MM patients were significantly higher than in healthy controls. in vitro study showed that the combination of FITC-conjugated anti-SLAMF7 antibody and FITC-targeted CART cells induced specific lysis of SLAMF7+ MM cells. Our results demonstrated that SLAMFs could be good targets for immunotherapies including antibody treatment and T cell-mediated immunotherapy.
|
